1 Overview

Definition

Pathogenesis

2 Clinical Manifestations and Grading Criteria

Clinical Manifestations: ARE: foreign body sensation when swallowing, followed by pain when eating or swallowing saliva, and gradually progressing to persistent retrosternal pain unrelated to swallowing, chest pain, choking, difficulty breathing, and nausea and vomiting. LRE: esophageal strictures or motility changes, subsequent difficulty swallowing or pain.

Grading Criteria: Grade 0-5

3 Examinations

Laboratory Tests

Esophagogram

Esophagoscopy and Pathological Biopsy

4 Diagnosis and Differential Diagnosis

Diagnosis

Differential Diagnosis: Suppurative Esophagitis, Esophageal Tuberculosis, Fungal Esophagitis, Viral Esophagitis

5 Risk Factors

Treatment-related factors: Radiation dose and dose-volume factors, Radiotherapy Techniques, Radiation fractionation, Concurrent Chemoradiation, Chemotherapy Regimens, Radiotherapy Combined with Targeted Drug Therapy, Radiotherapy Combined with Immune Checkpoint Inhibitors

Underlying Diseases and Individual Factors: gastroesophageal reflux disease, diabetes, hypertension, ECOG score, Laboratory indicators, nutritional status.

6 Treatment

Treatment of ARE: General management, Nutritional support treatment, Pharmacotherapy, Traditional Chinese Medicine (TCM) Treatment of LRE: Nickel-titanium alloy mesh stents and silicone membrane-covered stents

7 Prevention

Radiotherapy dose and mode

Drug prevention: Amifostine, GM-CSF, Glutamine,Others

8 Assessment and Health Education

Risk Assessment

Nutritional Assessment

Health Education

The implementation of efficient preventative measures can improve the quality of life. Preventive measures mainly focus on patient education, optimization of radiotherapy techniques (such as IMRT, IGRT, et al.), physical protection measures (injecting hyaluronic acid and collagen, inflatable balloon catheter), and pharmacological interventions (such as amifostine, misoprostol, sucralfate, et al.). Treating radiation-induced intestinal injury requires collaboration among a multidisciplinary team. Treatment options include observation, medication (systemic drugs, such as probiotics, antibiotics, NSAIDS, corticosteroids and topical enema drugs, such as sucralfate, antioxidants, GM-CSF, et al.), hyperbaric oxygen therapy, endoscopic treatment, and surgical treatment.

Comparison of Rapid Arc and Intensity Modulated Radiotherapy in a True Beam Linear Accelerator for 6 MV: Application of AAPM TG-119 tests in treatment planning and quality assurance.

The workflow scene presenting Hospital B requesting patient P's radiotherapy historical data to Hospital A on the platform of radiotherapy consortium blockchain (RTBC).

Postoperative stereotactic radiosurgery improves local tumor control in patients with metastatic brain cancer. However, the influence of timing on its therapeutic efficacy is unclear. In this study, we performed a meta-analysis and systematic literature review examining publications that reported the timing of postoperative SRS for patients with intracranial metastases. Our primary outcomes included median overall survival and rates of local and regional failure, while secondary outcomes examined the incidence of treatment-related adverse events. Correlations between median SRS timing and these variables were assessed using linear regression and publication bias was appraised via Egger's test. Our study resulted in 22 articles comprising 1338 patients. The median timing of adjuvant SRS spanned 14.5 to 41 days. There was a significant negative study-level correlation of median time to SRS with regional failure (p=0.043, R²=0.32) but not with overall survival (p=0.54, R²=0.03) or local failure (p=0.16, R²= 0.14). Additionally, there was significant heterogeneity within the reports (p<0.0001). In conclusion, our analysis demonstrated that postoperative SRS timing did not influence local failure rates which may in part be due to significant variability between individual study designs and patient demographics. Further research is warranted to elucidate the role of timing for postoperative SRS on oncologic outcomes.

Dual-energy CT (DECT) is a new imaging technology integrating functional imaging and molecular imaging. DECT can provide 12 categories of energy parameter image analysis, from which we can obtain multiple parameters to help us find diseases, differential diagnosis and predict prognosis and so on. DECT can be used as a supplementary noninvasive method for breast cancer, and it has great value in the diagnosis, treatment strategy and prognosis prediction of breast cancer in the future.